Filing Details

Accession Number:
0000919574-16-015622
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-30 15:55:00
Reporting Period:
2016-09-28
Filing Date:
2016-09-30
Accepted Time:
2016-09-30 15:55:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1100412 Array Biopharma Inc ARRY Pharmaceutical Preparations (2834) 841460811
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1425738 Redmile Group, Llc One Letterman Drive, Building D
Suite D3-300
San Francisco CA 94129
No No Yes No
1650527 Jeremy Green C/O Redmile Group, Llc
One Letterman Drive, Bldg D, Ste D3-300
San Francisco CA 94129
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Disposition 2016-09-28 2,492,578 $6.36 16,658,072 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
Footnotes
  1. This constitutes the weighted average sale price. The prices range from $6.25 to $6.76. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  2. These securities are directly owned by certain private investment vehicles and separately managed accounts managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.